Literature DB >> 16274990

Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase.

Ariamala Gopalsamy1, Alexis Aplasca, Gregory Ciszewski, Kaapjoo Park, John W Ellingboe, Mark Orlowski, Boris Feld, Anita Y M Howe.   

Abstract

A novel class of HCV NS5B RNA dependent RNA polymerase inhibitors containing 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran scaffolds were designed and synthesized. Optimization of the alkyl substituent in the pyran ring showed preference for an n-propyl group, while 5,8-disubstitution pattern is preferred for the aromatic region. Analog 19 displayed potent activity with an IC(50) of 50 nM against HCV NS5B enzyme and was selective over a panel of polymerases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16274990     DOI: 10.1016/j.bmcl.2005.08.114

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

1.  A cycloisomerization/Friedel-Crafts alkylation strategy for the synthesis of pyrano[3,4-b]indoles.

Authors:  Matthew R Medeiros; Scott E Schaus; John A Porco
Journal:  Org Lett       Date:  2011-07-08       Impact factor: 6.005

2.  Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets.

Authors:  David L Wyles; Kelly A Kaihara; Florin Vaida; Robert T Schooley
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

3.  DBU-mediated annulation of 2-aryl-3-nitro-2H-chromenes with 1,3-cyclohexanediones for the synthesis of benzofuro[2,3-c]chromenone derivatives.

Authors:  Chenlu Dai; Zengyang Xie; Xushun Qing; Naili Luo; Cunde Wang
Journal:  Mol Divers       Date:  2019-03-23       Impact factor: 2.943

4.  The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons.

Authors:  David L Wyles; Kelly A Kaihara; Brent E Korba; Robert T Schooley; James R Beadle; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

5.  Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.

Authors:  David L Wyles; Kelly A Kaihara; Robert T Schooley
Journal:  Antimicrob Agents Chemother       Date:  2008-03-10       Impact factor: 5.191

6.  Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase.

Authors:  Amaravadhi Harikishore; Enlin Li; Jia Jun Lee; Nam-Joon Cho; Ho Sup Yoon
Journal:  Mol Divers       Date:  2015-04-11       Impact factor: 2.943

7.  Antiviral therapy for hepatitis C virus: beyond the standard of care.

Authors:  Leen Delang; Lotte Coelmont; Johan Neyts
Journal:  Viruses       Date:  2010-03-29       Impact factor: 5.818

8.  Inhibitors for the hepatitis C virus RNA polymerase explored by SAR with advanced machine learning methods.

Authors:  Iwona E Weidlich; Igor V Filippov; Jodian Brown; Neerja Kaushik-Basu; Ramalingam Krishnan; Marc C Nicklaus; Ian F Thorpe
Journal:  Bioorg Med Chem       Date:  2013-03-29       Impact factor: 3.641

9.  Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.

Authors:  Lotte Coelmont; Suzanne Kaptein; Jan Paeshuyse; Inge Vliegen; Jean-Maurice Dumont; Grégoire Vuagniaux; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.